TuHURA's AML IND clearance tests how small biotechs fund early-phase oncology trials

What happened

The US FDA has allowed TuHURA Biosciences to proceed with a Phase 1b study of TBS-2025, a VISTA-targeting antibody, in relapsed or refractory acute myeloid leukaemia (AML) with mutant NPM1. The clearance was disclosed on 13 November 2026 alongside the company's third-quarter results, which report $1.9 million in cash.

In general terms, an IND clearance means the agency has not placed the proposed study on clinical hold, so the sponsor may begin dosing once its other prerequisites are in place. Those typically include institutional review board approval and site activation. The records do not say when enrolment will start, how many patients are planned, which sites will take part, or how the study will be financed. Those details are not yet known from the material available.

Why the cash figure matters

Regulatory clearance and operational readiness are separate milestones. A cash balance of $1.9 million, as reported, is a notable number next to a leukaemia trial that must recruit a hard-to-treat population. The records do not indicate whether the figure reflects subsequent financing or whether other funding is expected, so any conclusion about the study's timeline would be speculation.

The practical point for the clinical trials desk is that an IND clearance headline is not a reliable proxy for study start. Partners, CROs and site networks dealing with early-stage sponsors should look at the financial disclosures alongside the regulatory news.

Regulatory context: the new FDA draft guidance does not cover this trial

Within the same week, FDA issued a draft guidance on early-phase IND protocol recommendations for solid tumours. It addresses first-in-human trials and products with limited human experience, and it was published by the Oncology Center of Excellence. Comments are open until 11 January 2027.

The draft explicitly excludes haematologic malignancies. TuHURA's AML study therefore falls outside its scope. Sponsors of blood-cancer first-in-human or early-phase studies cannot assume the same protocol recommendations apply, and should raise protocol design questions directly with the agency. The records do not say whether FDA plans a comparable document for haematologic cancers.

The guidance appears in two FDA-linked listings, one on the agency's guidance page dated 10 November and one in the Federal Register dated 12 November. Teams tracking the comment deadline should work from the Federal Register notice.

Parallels elsewhere in the pipeline

Two other records from the same days show how smaller sponsors manage resources around clinical milestones. Bluejay Diagnostics has finished enrolment in its pivotal SYMON-II study of the Symphony IL-6 sepsis test and secured a backup cartridge site. It targets a 510(k) filing in the first half of 2027, but its $7.38 million in cash runs only to the second quarter of 2027. A diagnostic 510(k) pathway differs from a drug IND, but the pattern is similar: the scientific and regulatory timetable is tightly bound to the cash runway.

Oncolytics Biotech and Coherus Oncology have agreed that Coherus will supply its LOQTORZI (toripalimab) for a planned US study combining it with the investigational oncolytic virus pelareorep in squamous cell anal carcinoma. The records give no further terms. Combination-supply agreements of this kind are one common way for sponsors to secure a partner's product for a study, though the financial details of this deal are not stated.

Who is affected and what to watch

Affected groups include CROs and sites considering work on relapsed or refractory NPM1-mutant AML, regulatory teams planning haematology-oncology INDs, and investors and partners tracking TuHURA, though VigiEye offers no investment advice.

Several points remain open: the start date and size of the Phase 1b, any new financing disclosed by TuHURA, and whether the FDA's solid-tumour draft changes after the 11 January 2027 comment deadline. Also unresolved is whether the agency will issue similar recommendations for haematologic malignancies.